13D Filing: James E. Flynn and DFB Healthcare Acquisitions Corp.

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE
13D

[Rule 13d-101]

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §
24.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13D-2(a)

(Amendment No. )*

DFB
Healthcare Acquisitions Corp.

(Name
of Issuer)

Common
Stock, par value $0.0001 per share

(Title
of Class of Securities)

23291E208

(CUSIP
Number)

(Name,
Address and Telephone Number of Person Authorized to Receive Notices and Communications)

February
21, 2018

(Date
of Event which Requires Filing of this Statement)

If the filing person
has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing
this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐.

Note: Schedules
filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7
for other parties to whom copies are to be sent.

(Continued on following
pages)
(Page 1 of 15 Pages)

* The remainder of this cover page shall be filled out for a
reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page
shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).

SCHEDULE 13D

(1) Comprised of 2,500,000 shares held by Deerfield Private
Design Fund IV, L.P. and 6,967,500 shares held by Deerfield/RAB Ventures, LLC.

(2) Does not include 833,333 shares of common stock issuable
upon exercise of warrants held by Deerfield Private Design Fund IV, L.P. and 4,333,333 shares of common stock issuable upon exercise
of warrants held by Deerfield/RAB Ventures, LLC, which are not presently exercisable and are not exercisable within 60 days from
the date hereof.

SCHEDULE 13D

(3) Comprised of 2,500,000 shares held by Deerfield Private
Design Fund IV, L.P. and 6,967,500 shares held by Deerfield/RAB Ventures, LLC.

(4) Does not include 833,333 shares of common stock issuable
upon exercise of warrants held by Deerfield Private Design Fund IV, L.P. and 4,333,333 shares of common stock issuable upon exercise
of warrants held by Deerfield/RAB Ventures, LLC, which are not presently exercisable and are not exercisable within 60 days from
the date hereof.

SCHEDULE 13D

(5) Comprised of 2,500,000 shares held by Deerfield Private
Design Fund IV, L.P., 6,967,500 shares held by Deerfield/RAB Ventures, LLC and 30,000 shares held by Steven Hochberg, an employee
of Deerfield Management Company and a member of the Issuer’s board of directors, for the benefit, and subject to the direction,
of Deerfield Management Company.

(6) Does not include 833,333 shares of common stock issuable
upon exercise of warrants held by Deerfield Private Design Fund IV, L.P. and 4,333,333 shares of common stock issuable upon exercise
of warrants held by Deerfield/RAB Ventures, LLC, which are not presently exercisable and are not exercisable within 60 days from
the date hereof.

SCHEDULE 13D

(7) Comprised of 2,500,000 shares held by Deerfield Private
Design Fund IV, L.P., 6,967,500 shares held by Deerfield/RAB Ventures, LLC and 30,000 shares held by Steven Hochberg, an employee
of Deerfield Management Company and a member of the Issuer’s board of directors, for the benefit, and subject to the direction,
of Deerfield Management Company.

(8) Does not include 833,333 shares of common stock issuable
upon exercise of warrants held by Deerfield Private Design Fund IV, L.P. and 4,333,333 shares of common stock issuable upon exercise
of warrants held by Deerfield/RAB Ventures, LLC, which are not presently exercisable and are not exercisable within 60 days from
the date hereof.

SCHEDULE 13D

(9) Comprised of shares held by Deerfield/RAB Ventures, LLC.

This Schedule 13D is filed by (i) Deerfield
Mgmt IV, L.P. (“Deerfield Mgmt IV”), (ii) Deerfield Private Design Fund IV, L.P. (“Deerfield Private
Design Fund IV”), (iii) Deerfield Management Company, L.P. (“Deerfield Management”), (iv) James E.
Flynn, a natural person (“Flynn”), and (v) Steven I. Hochberg, a natural person (“Hochberg”
and collectively with Deerfield Mgmt IV, Deerfield Private Design Fund IV, Deerfield Management and Flynn, the “Reporting
Persons”), with respect to the common stock of DFB Healthcare Acquisitions Corp.

This Statement on Schedule 13D relates to the shares of common
stock, par value $0.0001 per share (the “Common Stock”), of DFB Healthcare Acquisitions Corp., a Delaware corporation
(the “Company”). The address of the Company’s principal executive offices is 780 Third Avenue, New York, NY
10017.

Item 2. Identity and Background.

On August 21, 2017, Deerfield
Management voluntarily agreed to settle an SEC administrative proceeding relating to alleged violations of Section 204A of the
Investment Advisers Act of 1940 (the “Advisers Act”), without admitting or denying the SEC’s allegations,
pursuant to an order under Section 203(e) and 203(k) of the Advisers Act (the “Order”). The Order resolved the
SEC’s allegations that Deerfield Management, from 2012 through 2014, violated Section 204A of the Advisers Act by failing
to establish, maintain, and enforce policies and procedures reasonably designed to prevent the misuse of material, nonpublic information,
particularly taking into consideration the nature of Deerfield Management’s business. The Order alleged that, as part of
Deerfield Management’s research in the healthcare sector, Deerfield Management engaged third party consultants and research
firms, including firms that specialized in providing “political intelligence” regarding upcoming regulatory and legislative
decisions, that Deerfield Management employees based certain trading recommendations on such information, and that hedge funds
advised by Deerfield Management then made those trades. The Order required Deerfield Management to cease and desist from committing
or causing any violations and any future violations of Section 204A of the Advisers Act, censured Deerfield Management and provided
that Deerfield Management would pay disgorgement and interest of $811,695 and a civil money penalty of $3,946,267.

Other than as set forth above
in this Item 2(e), during the last five years, none of the Reporting Persons, nor, to the best of each of the Reporting Person’s
knowledge, any of the persons listed on Schedule A attached hereto, has been a party to a civil proceeding of a judicial
or administrative body of competent jurisdiction and, as a result of such proceeding, was or is subject to a judgment, decree or
final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws
or finding any violation with respect to such laws.

The Reporting Persons have entered into
a Joint Filing Agreement, a copy of which is attached hereto as Exhibit A.

The Reporting Persons may be deemed to
beneficially own 6,967,500 shares of Common Stock held by Deerfield/RAB Ventures, LLC (the “Sponsor”). On February
15, 2018, prior to the Company’s initial public offering (the “IPO”), Deerfield Private Design Fund IV
acquired 12,500 units (“Units”) of the Sponsor (the “Initial Sponsor Units”), representing
a 50% membership interest in the Sponsor, in exchange for a capital contribution of $12,500. The Sponsor may be required to forfeit
up to 921,848 of the shares of Common Stock initially purchased by the Sponsor in a private placement prior to the IPO (“Founder
Shares”) depending upon the extent to which the underwriters in the IPO exercise their over-allotment option.

On February 21, 2018, Deerfield Private
Design Fund IV purchased 2,500,000 Units of the Company for $10.00 per Unit, or $25,000,000 in the aggregate, in the IPO. Each
Unit consists of (i) one share of common stock, par value $0.0001 per share (“Common Stock”) and (ii) one-third
of a redeemable warrant (the “Public Warrants”). Each whole Public Warrant entitles the holder to purchase one
share of Common Stock upon the terms set forth therein.

In addition, on February 21, 2018, contemporaneously
with the closing of the IPO, the Sponsor purchased an aggregate of 4,333,333 warrants (the “Private Placement Warrants”
and together with the Public Warrants, the “Warrants”) at a price of $1.50 per Private Placement Warrant, for
an aggregate purchase price of $6,500,000. On February 16, 2018, Deerfield Private Design Fund IV contributed $3,250,000 to the
Sponsor for 3,250,000 Units of the Sponsor (the “Additional Units” and, together with the Initial Units, the
“Sponsor Units”) to fund 50% of the purchase price for the Private Placement Warrants. RAB Ventures (DFB) LLC
(“RAB”), which holds Units of the Sponsor representing 50% of the membership interests in the Sponsor, also
contributed $3,250,000 to the Sponsor to fund the Sponsor’s acquisition of the Private Placement Warrants.

Deerfield Private Design Fund IV utilized
available cash assets to acquire the Sponsor Units and the Units it purchased in the IPO.

Hochberg, an employee of Deerfield Management,
serves as a director of the Company and, on December 29, 2017, the Sponsor
transferred 30,000 shares of Common Stock to Hochberg for his service as a director of the Company. The Common Stock held by Steven
Hochberg and reported herein is held for the benefit, and subject to the direction, of Deerfield Management. Up to 3,913 of the
shares of Common Stock held by Hochberg are subject to forfeiture depending upon the extent to which the underwriters in the IPO
exercise their over-allotment option.

The information set forth in Item 3 and
Item 6 is incorporated herein by reference.

The Reporting Persons have acquired the shares reported
herein for investment purposes. As set forth in the Company’s IPO prospectus, the Company was formed for the purpose of
effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination
with one or more businesses (a “Business Combination”). The members of the Sponsor are Deerfield Private
Design Fund IV and RAB (an affiliate of Richard Barasch, the President, Chief Executive Officer and Chairman of the Company
and manager of the Sponsor). Mr. Hochberg, an employee of Deerfield Management, is a manager of the Sponsor and serves on the
Company’s board of directors. The IPO prospectus discloses the Company’s management team’s belief
that Deerfield Management’s expertise, record of generating proprietary investment opportunities, and experience
evaluating, structuring and executing transactions in the healthcare industry, as well as Richard Barasch’s (an
affiliate of the Sponsor and potential member of a “group” with the Reporting Persons) track record in the
healthcare services sector, provide the Company with a competitive advantage. Consistent with the Sponsor and its
Members’ and managers’ anticipated roles with respect to the objectives of the Company, the Reporting Persons
anticipate that they and their representatives will, and/or may take action to cause the Sponsor or its representatives to,
communicate with members of the Company’s board of directors, members of the Company’s management and/or other
shareholders of the Company from time to time with respect to potential investment and acquisition opportunities and
operational, strategic, financial or governance matters, or otherwise work with management and the Company’s board of
directors to identify, evaluate, structure, negotiate, execute or otherwise facilitate a Business Combination. Among other
things, the Reporting Persons may introduce the Company to potential candidates for a Business Combination, or propose one or
more Business Combinations with potential candidates, which may include candidates that are affiliates of one or more
Reporting Persons or in which one or more Reporting Persons otherwise has an equity or other interest. In addition, as a
member of the board of directors of the Company, Hochberg will be involved in reviewing transactions that may result in a
Business Combination.

In connection with its acquisition of Units of the Company in
the IPO, Deerfield Private Design Fund IV entered into the Letter Agreement, dated as of February 15, 2018 (the “Letter
Agreement”), by and between the Company and Deerfield Private Design Fund IV. Pursuant to the terms of the Letter Agreement,
the Company agreed not to consummate its initial Business Combination without the consent of Deerfield Private Design Fund IV (which
is not to be unreasonably withheld). If the Company seeks stockholder approval of a proposed initial Business Combination for which
Deerfield Private Design Fund IV has granted consent, then in connection with such proposed Business Combination, Deerfield Private
Design Fund IV has agreed (i) to vote any shares of Common Stock of the Company owned by it in favor of such proposed Business
Combination and (ii) not to redeem any shares of Common Stock owned by it in connection with such stockholder approval.

If the Company seeks stockholder approval of its initial Business
Combination and the Company does not conduct redemptions in connection with its Business Combination pursuant to the tender offer
rules, the Reporting Persons (and/or the Sponsor and its affiliates) may purchase shares of Common Stock in privately negotiated
transactions or in the open market either prior to or following the completion of the initial Business Combination, although no
such party is under any obligation to do so. Such a purchase may include a contractual acknowledgement that the selling stockholder,
although still the holder of the shares as of the record date for redemption, is no longer the owner thereof and therefore agrees
not to exercise its redemption rights. In the event that the Reporting Persons (and/or the Sponsor and its affiliates) purchase
shares in privately negotiated transactions from public stockholders who have already elected to exercise their redemption rights,
such selling stockholders would be required to revoke their prior elections to redeem their shares. The purpose of any such purchases
could be to vote such shares in favor of the initial Business Combination and thereby increase the likelihood of obtaining stockholder
approval of the initial Business Combination or to satisfy a closing condition in an agreement with a target that requires the
Company to have a minimum net worth or a specified amount of cash at the closing of such Business Combination, where it appears
that such requirement would otherwise not be met. This may result in the completion of the Company’s initial Business Combination
that may not otherwise have been possible.

Item 5. Interest in Securities of the Issuer.

(a)

(1)      Deerfield
Mgmt IV

Number
of shares: 9,467,500 (comprised of shares held by Deerfield Private Design Fund IV and the Sponsor)

Percentage of shares: 30.30%

(2)      Deerfield
Management

Percentage of shares: 30.39%

(3)      Deerfield
Private Design Fund IV

Number
of shares: 9,467,500 (comprised of shares held directly and by the Sponsor)

Percentage of shares: 30.30%

(4)      Flynn

Percentage of shares: 30.39%

(5)      Hochberg

Number
of shares: 6,967,500 (comprised of shares held by the Sponsor)

Percentage of shares: 22.3%

(b)

(1)      Deerfield
Mgmt IV

Sole power to vote or direct the vote: 0

Shared power to vote or direct the vote:
9,467,500

Sole power to dispose or to direct the disposition:
0

Shared power to dispose or direct the disposition:
9,467,500

(2)      Deerfield
Management

Sole power to vote or direct the vote: 0

Shared power to vote or direct the vote:
9,497,500

Sole power to dispose or to direct the disposition:
0

Shared power to dispose or direct the disposition:
9,497,500

(3)      Deerfield Private Design Fund IV

Sole power to vote or direct the vote: 0

Shared power to vote or direct the vote:
9,467,500

Sole power to dispose or to direct the disposition:
0

Shared power to dispose or direct the disposition:
9,467,500

(4)      Flynn

Sole power to vote or direct the vote: 0

Shared power to vote or direct the vote:
9,497,500

Sole power to dispose or to direct the disposition:
0

Shared power to dispose or direct the disposition:
9,497,500

(4)      Hochberg

Sole power to vote or direct the vote: 0

Shared power to vote or direct the vote:
6,967,500

Sole power to dispose or to direct the disposition:
0

Shared power to dispose or direct the disposition:
6,967,500

Flynn is the sole member of the general
partner of each of Deerfield Mgmt IV and Deerfield Management. Deerfield Mgmt IV is the general partner, and Deerfield Management
is the investment manager, of Deerfield Private Design Fund IV. Hochberg, an employee of Deerfield Management and a director of
the Company, also serves as Deerfield Private Design Fund IV’s designee on the board of managers of the Sponsor, which consists
of two managers.

Each Reporting Person may be deemed to
be a member of a “group” for purposes of the Exchange Act with the Sponsor and RAB (the other member of the Sponsor),
and Richard Barasch. The Reporting Persons, the Sponsor, RAB and Mr. Barasch may be deemed to collectively beneficially own an
aggregate of 9,497,500 shares of Common Stock, or 30.39% of the issued and outstanding shares of Common Stock. The share ownership
reported for the Reporting Persons does not include any shares of Common Stock held by the other member of the Sponsor or Mr. Barasch.
Each Reporting Person disclaims beneficial ownership of any shares of Common Stock beneficially owned by the other member of the
Sponsor, except with respect to the shares owned by the Sponsor as disclosed in this Schedule 13D.

(c) Except as set forth in Items 3 and
4 of this Schedule 13D, the Reporting Persons have not engaged in any transactions in the Company’s securities during the
past 60 days.

(d) Except as described in this paragraph, as of the date of
this Schedule 13D, no person other than the Reporting Persons is known to the Reporting Persons to have the right to receive or
the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock covered by this
Schedule 13D. RAB holds 50% of the outstanding Units of the Sponsor and has designated Richard Barasch as a member of the board
of managers of the Sponsor. Mr. Barasch and Hochberg, as managers of the Sponsor, have the right, acting together, to direct the
receipt of dividends in respect of, and proceeds from the sale of, the Founder Shares in accordance with the terms of the LLC Agreement
(as defined in Item 6 below) of the Sponsor.

(e) Not applicable.

Letter Agreement

On February 15, 2018, the Company and Deerfield Private Design
Fund IV entered into the Letter Agreement. Pursuant to the terms of the Letter Agreement, the Company shall not consummate its
initial Business Combination without the consent of Deerfield Private Design Fund IV. If the Company seeks stockholder approval
of a proposed Business Combination for which Deerfield Private Design Fund IV has granted consent, then in connection with such
proposed Business Combination, Deerfield Private Design Fund IV has agreed (i) to vote any shares of Common Stock of the Company
owned by it in favor of such proposed Business Combination and (ii) not to redeem any shares of Common Stock owned by it in connection
with such stockholder approval.

Registration Rights Agreement

On February 15, 2018, the Company, the Sponsor and the other
parties thereto entered into a Registration Rights Agreement (the “Registration Rights Agreement”). Pursuant
to the terms of the Registration Rights Agreement, the Company granted certain registration rights to the Sponsor in respect of
the Private Placement Warrants and the Founder Shares, the shares of Common Stock underlying the Private Placement Warrants and
certain warrants that may be issued upon conversion of working capital loans (including the shares of Common Stock underlying such
warrants). In addition, the holders of the Founder Shares and Private Placement Warrants will be entitled to make up to three demands,
excluding short form registration demands, that the Company register such securities for sale under the Securities Act. Further,
these holders will have “piggy-back” registration rights to include such securities in other registration statements
filed by the Company and rights to require the Company to register for resale such securities pursuant to Rule 415 under the
Securities Act.

Warrant Agreement

The Public Warrants are governed by the terms of the Warrant
Agreement (the “Warrant Agreement”), dated February 15, 2018, between the Company and Continental Stock Transfer
& Trust Company (the “Warrant Agent”). Each whole Warrant entitles the registered holder to purchase one
share of the Common Stock at a price of $11.50 per share, subject to adjustment described therein, at any time commencing on the
later of: (i) the date that is 30 days after the first date on which the Company completes a Business Combination, or (ii) the
date that is 12 months from the date of the closing of the IPO, and terminating at 5:00 p.m., New York City time on the earlier
to occur of: (x) the date that is 5 years after the date on which the Company completes its initial Business Combination,
(y) the liquidation of the Company in accordance with the Company’s amended and restated certificate of incorporation,
as amended from time to time, if the Company fails to complete a Business Combination, or (z) other than with respect to the
Private Placement Warrants then held by the Sponsor or its permitted transferees, the date the Company elects to redeem all the
Warrants.

Warrant Purchase Agreement

On February 15, 2018, the Company and the Sponsor entered into
a Warrant Purchase Agreement (the “Warrant Purchase Agreement”). Pursuant to the terms of the Warrant Purchase
Agreement, the Sponsor agreed to purchase from the Company 4,333,333 Private Placement Warrants for $6,500,000 (which were purchased
upon consummation of the IPO), and up to 500,000 warrants if the underwriters’ option to purchase additional Units is exercised
in full, as described below.

The Private Placement Warrants, which are governed by the terms
of the Warrant Agreement. are identical to the Public Warrants, except that so long as they are held by the Sponsor or any of its
permitted transferees, the Private Placement Warrants: (i) may be exercised for cash or on a cashless basis (whereas the Public
Warrants may only be exercised for cash), (ii) may not be transferred, assigned or sold until 30 days after the completion
by the Company of an initial Business Combination and (iii) will not be redeemable by the Company. Further, pursuant to the
terms of the Registration Rights Agreement, the Company granted certain registration rights to the Sponsor relating to the Private
Placement Warrants and the shares underlying the Private Placement Warrants.

In the event that the over-allotment option set forth in that
certain Underwriting Agreement, dated as of February 15, 2018 (the “Underwriting Agreement”), by and among the
Company, Goldman Sachs & Co. LLC and Deutsche Bank Securities Inc. is exercised in full or in part, the Sponsor has agreed
to purchase up to an additional 500,000 Private Placement Warrants (the “Additional Private Placement Warrants”),
in the same proportion as the underwriters’ option to purchase additional units that is exercised. Simultaneously with such
purchase of Additional Private Placement Warrants, as payment in full for the Additional Private Placement Warrants being purchased
thereunder, and at least 1 business day prior to the closing of all or any portion of the over-allotment option, the Sponsor
agreed to pay $1.50 per Additional Private Placement Warrant, up to an aggregate amount of $750,000.

Limited Liability Company Agreement of Deerfield/RAB Ventures,
LLC

On February 15, 2018, RAB and Deerfield Private Design Fund
IV (each individually, a “Member” and, collectively, the “Members”) entered into the Limited
Liability Company Agreement (the “LLC Agreement”) of Deerfield/RAB Ventures, LLC. In consideration for an initial
capital contribution of $12,500 by each of the Members for a 50% interest in the Sponsor, each of the Members received 12,500 Units.
Prior to the filing of the registration statement for the Company in connection with the IPO, each Member contributed an additional
$3,250,000 to the Company and received the like number of Units, in order to fund the obligations to acquire the Private Placement
Warrants pursuant to the terms of the Warrant Purchase Agreement. In the event that the Company is (i) required to purchase additional
Private Placement Warrants pursuant to the Warrant Purchase Agreement, or (ii) is afforded the opportunity to acquire (and did
acquire) additional securities of the Company in connection with the upsizing of the Company’s public offering beyond the
amount contemplated by the over-allotment option contemplated in the Underwriting Agreement (such additional securities together
with additional Private Placement Warrants, the “Additional Securities”) then, no less than 3 days prior to
the closing of any such purchase, Deerfield Private Design Fund IV shall contribute to the Company an amount equal to the purchase
price of such Additional Securities, and shall receive a like number of Units.

The foregoing summaries of certain terms of the Letter Agreement,
Registration Rights Agreement, Warrant Agreement, Warrant Purchase Agreement and the LLC Agreement are not complete and are qualified
in their entirety by reference to the full text of such documents, copies of which are filed, or incorporated by reference, as Exhibits
1-5 to this Schedule 13D.

Exhibit 2

Registration Rights Agreement, dated as of February 15, 2018, between the DFB Healthcare Acquisitions
Corp., Deerfield/RAB Ventures, LLC and the Initial Stockholders (incorporated by reference to Exhibit 10.3 to the Company’s
Current Report on Form 8-K filed with the SEC on February 22, 2018). 

Exhibit 3

Warrant Agreement, dated February 15, 2018, between DFB Healthcare Acquisitions Corp. and Continental
Stock Transfer & Trust Company (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K
filed with the SEC on February 22, 2018). 

Exhibit 4

Warrant Agreement, dated February 15, 2018, between DFB Healthcare Acquisitions Corp. and Deerfield/RAB
Ventures, LLC (incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K filed with the SEC on
February 22, 2018). 

Exhibit 5

Limited Liability Company Agreement of Deerfield/RAB Ventures, LLC, dated as of February 15, 2018, by
and between RAB Ventures (DFB) LLC and Deerfield Private Design Fund IV, L.P. *

Cusip No. 23291E208

SIGNATURE

After reasonable inquiry
and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true,
complete and correct.

Dated: March 5, 2018

Cusip No. 23291E208

Schedule A

General Partner of Deerfield Mgmt IV,
L.P.

The general partner of Deerfield Mgmt IV
is J.E. Flynn Capital IV, LLC. The address of the principal business and/or principal office of Deerfield Mgmt IV and J.E. Flynn
Capital IV, LLC is 780 Third Avenue, 37^th Floor, New York, New York 10017.

General Partner of Deerfield Private Design Fund
IV, L.P.

The general partner of Deerfield Private
Design Fund IV is Deerfield Mgmt IV. The address of the principal business and/or principal office of Deerfield Mgmt IV and Deerfield
Private Design Fund IV is 780 Third Avenue, 37^th Floor, New York, New York 10017.

General Partner of Deerfield Management
Company, L.P.

The general partner of Deerfield Management
is Flynn Management LLC. The address of the principal business and/or principal office of Deerfield Management and Flynn Management
LLC is 780 Third Avenue, 37^th Floor, New York, New York 10017.

Cusip No. 23291E208

Exhibit Index

Exhibit 2

Registration Rights Agreement, dated as of February 15, 2018, between the DFB Healthcare Acquisitions
Corp., Deerfield/RAB Ventures, LLC and the Initial Stockholders (incorporated by reference to Exhibit 10.3 to the Company’s
Current Report on Form 8-K filed with the SEC on February 22, 2018). 

Exhibit 3

Warrant Agreement, dated February 15, 2018, between DFB Healthcare Acquisitions Corp. and Continental
Stock Transfer & Trust Company (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K
filed with the SEC on February 22, 2018). 

Exhibit 4

Warrant Agreement, dated February 15, 2018, between DFB Healthcare Acquisitions Corp. and Deerfield/RAB
Ventures, LLC (incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K filed with the SEC on
February 22, 2018).